UK government targets manufacturing as it eyes £41bn life science sector growth
The UK Government will enhance manufacturing and commercialisation as it looks to harness the value of the life sciences sector…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
GSK’s Blenrep US comeback hindered by eye safety concerns
GSK’s plan to bring blood cancer drug Blenrep (belantamab mafodotin) back to markets has hit a stumbling block, after the…
-
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing…
-
LEO Pharma secures rights to Boehringer’s Spevigo for $105m
Danish dermatology leader LEO Pharma has bought the rights to Boehringer Ingelheim’s psoriasis drug Spevigo (spesolimab) for €90m ($105m), strengthening…
-
WHO endorses Gilead’s Yeztugo for HIV prevention
The World Health Organization (WHO) is recommending the use of Gilead Sciences’ newly approved injectable version of lenacapavir to fight…
-
GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients
GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV)…
-
Leading medical groups sue RFK Jr and HHS over ‘hostile’ vaccine policies
Several leading medical organisations have filed a lawsuit against US health Secretary Robert F Kennedy (RFK) Jr and the US…
-
J&J eyes prostate cancer label expansion for Akeega
Johnson & Johnson (J&J) has applied to the European Medicines Agency (EMA) to extend the indication of Akeega (niraparib and…
-
AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer
AstraZeneca has added another indication to its blockbuster immunotherapy Imfinzi (durvalumab), gaining European approval to treat a type of bladder…
-
Big pharma braces for revenue headwinds as patent expiries loom
One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for…